The Clinical Observation Of Changyuning About The Serum C-Reactive Protein In Patients With Active Ulcerative Colitis

Objective:By observing the changes of DAI score and the serum levels of CRP in patients with active UC before and after treatment using changyuning, then evaluate the efficacy of changyuning on patients with UC and investigate the influence and clinical significance of changyuning on the serum CRP in patients with active UC, provide an objective theoretical basis for clinical diagnosis and treatment of active UC.Methods:Selected90cases of patients with active UC that met the inclusion criteria, then divided it into three groups of30patients randomly. The Traditional Chinese Medicine group was given changyuning and mesalazine was used in the western medicine group, when the group combined TCM with western medicine received changyuning and mesalazine. Observe the improvement of the intestinal mucosa under colonoscopy after4weeks of continuous administration, meanwhile the changes in inflammatory activity index (DAI) and the serum levels of CRP was recorded. Using SPSS17.0statistical software for data processing statistics.Results:(1) The DAI scores within each group after treatment were significantly lower than before (P<0.05), which showing no significant difference when pairwise comparisons (P>0.05). After treatment, DAI scores between the TCM group and western medicine group was no statistical difference (P>0.05), but higher than the group combined TCM with western medicine (P<0.05).(2) Comparison of the efficacy of the intestinal mucosa under colonoscopy after treatment, the total effective rate among the three groups showed a difference in evidence (P<0.05) that the group combined TCM with western medicine have a better efficacy than the TCM group and western medicine group (P<0.05), but there was no obvious difference between the efficacy of TCM group and western medicine group (P>0.05).(3) The differences of serum CRP levels before and after treatment within each group were statistically significant (P<0.05), it can be considered that the serum levels of CRP after treatment were decreased evidently compared with that treatment has not been implemented.Conclusion:(1) Both changyuning and mesalazine can reduce the DAI score of patients with active UC significantly, they repair intestinal mucosal lesions and have an better therapeutic effect on patients with active UC.(2) Rather than using changyuning or mesalazine merely, it has a better performance in terms of efficacy on patients with active UC when changyuning and mesalazine were used in combination.(3) Changyuning can plays an important role in relieving symptoms in patients with active UC significantly, repairing the colonic mucosa ulcers effectively and reducing the serum levels of CRP in active UC.